AstraZeneca presented data from the confirmatory Phase III SOLO-2 trial demonstrating a statistically significant and clinically meaningful improvement of progression-free survival among patients treated with Lynparza (olaparib) compared to placebo.
Eli Lilly and Co. said its MONARCH 2 trial of abemaciclib met the primary endpoint of progression-free survival. The phase III study evaluated abemaciclib, a cyclin-dependent kinase 4 and CDK 6 inhibitor, in combination with fulvestrant in women with hormone-receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer who have relapsed or progressed after endocrine therapy.
The New England Journal of Medicine published results from a nearly 11-year follow-up study, that showed an estimated overall survival rate of 83.3 percent.
Amgen announced positive results from a planned overall survival interim analysis of the Phase III head-to-head ENDEAVOR trial.
Scientists and patient advocates have largely overlapping agendas, but, ultimately, their agendas diverge, said Fran Visco, president of the National Breast Cancer Coalition, the organization that ushered in a new era in the politics of cancer research and delivery of care.
President's Donald Trump's budget proposal should be treated as a genuine, credible threat to science, said Richard Klausner, a biotechnology entrepreneur who led NCI through the years of the doubling of the NIH budget.
The White House budget blueprint to slash NIH funding by 18.3 percent in fiscal 2018 is just a proposal, NCI Acting Director Douglas Lowy said at the meeting of the Board of Scientific Advisors March 21.
Beth Caldwell, a patient with metastatic neuroendocrine breast cancer, has more to lose than anyone else in the controversy over President Donald Trump's proposed cuts to the NIH budget.
White House spokesman Sean Spicer said the cuts proposed by the administration will help eliminate inefficiency and duplication at NIH. At a White House press briefing March 16, Spicer was asked to justify his boss's proposal to gut biomedical research funding:
